INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $14,517,000 | +3943.7% | 277,359 | +2519.8% | 0.03% | +3000.0% |
| Q1 2021 | $359,000 | -58.3% | 10,587 | -81.1% | 0.00% | -85.7% |
| Q1 2020 | $860,000 | -12.6% | 55,926 | +95.0% | 0.01% | +133.3% |
| Q4 2019 | $984,000 | -33.8% | 28,680 | -85.6% | 0.00% | -40.0% |
| Q3 2019 | $1,487,000 | -49.5% | 199,020 | -12.2% | 0.01% | -50.0% |
| Q2 2019 | $2,942,000 | -17.1% | 226,693 | -22.2% | 0.01% | -16.7% |
| Q1 2019 | $3,548,000 | +61.7% | 291,334 | +51.2% | 0.01% | +33.3% |
| Q4 2018 | $2,194,000 | +8.2% | 192,653 | +100.1% | 0.01% | +28.6% |
| Q1 2018 | $2,027,000 | -10.9% | 96,274 | -38.7% | 0.01% | 0.0% |
| Q4 2017 | $2,274,000 | +354.8% | 157,074 | +649.9% | 0.01% | +250.0% |
| Q1 2015 | $500,000 | – | 20,947 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |